Neonatal cholestasis following total parenteral nutrition. Toxic liver disease, unspecified
Conditions
Interventions
Intervention 1: Intervention group: TPN+ UDCA (20 mg/kg per day divided into three daily doses) in the intervention group UDCA 20 mg/kg per day (solution prepared with a concentration of 30 mg/ml from
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
No minimum to 1 Years
Inclusion criteria
Inclusion criteria: Having parental consent to participate in the study Having an indication for TPN (prematurity (children) and NEC, gastroschisis, severe jejunoileal atresia, loss equal to or greater than 50% of expected small bowel length for gestational age at surgery) total parenteral nutrition for more than two weeks Primary serum conjugated bilirubin less than 2 mg/dl Negative diagnostic test for other possible causes of conjugated hyperbilirubinemia Newborns and infants admitted to the NICU
Exclusion criteria
Exclusion criteria: Patients with lack of parental consent to participate in the study Patients with multiple congenital malformations, life-threatening renal or cardiovascular disease, evidence of biliary tract abnormalities, or evidence of other forms of cholestatic liver disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cholestasis (Primary serum conjugated bilirubin greater than 2 mg/dl). Timepoint: Time periods before receiving the drug, 3 days later, 1 week later, 2 weeks later, 3 weeks later and 4 weeks after receiving the drug. Method of measurement: Bilirubin test laboratory kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammadreza Mollaabbasi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed